Lactobacillus rhamnosus
Phase 2Small molecule
Lactobacillus rhamnosus is one of 81 small molecule programs targeting Leukemia. It is currently in Phase 2.
2
Indications
3
Total Trials
2
Active Trials
80
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Leukemia
#DrugCompanyPhaseTrials
1Trexall
Alnylam PharmaceuticalsPhase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Rituxan
RochePhase 3
Novantrone
PfizerPhase 3
Leukine
SanofiPhase 3
Wellcovorin
EEastern Cooperative Oncology Group
Phase 3
Mesnex
BBaxter Healthcare Corporation
Phase 3
Elspar
DDutch Childhood Oncology Group
Phase 3
Purinethol
SStason
Phase 3
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Leukemia1 trial
Heart Disease1 trial
The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease
Active, not recruiting·—·N/A·NCT06872320·120 enrolled
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Lactobacillus rhamnosus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- NNancy Zucker